BioNTech (BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

If you are interested in BNTX stock information, you might also be interested in competitors like NYSE:JNJ.

With a P/E ratio of 0.00, the stock appears relatively cheap compared to its index ^COMP at the moment.

The market capitalization of BioNTech is currently at $41.64 B. This places it among the high capitalized companies.

The book value reported in the balance sheet results in a P/B ratio of 2.47.

With one share of BioNTech investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.

For the risk analysis, the low beta factor should be noted, which is currently at a value of -0.29. The price of the stock NasdaqGS:BNTX is therefore subject to moderate fluctuations in relation to the overall market.

63.3% of BNTX Stocks is owned by insiders.

Since not enough Wall Street analysts have published their estimates, we are unfortunately unable to provide a reliable price target for the BNTX stock.

NasdaqGS:BNTX has a 52 week range of $121.32 - $464.00 and is currently trading around $161.73.

The low short sale ratio indicated that the value might increase in the foreseeable future.